Announcing the much awaited safety and efficacy data from phase-3 clinical trials of Covaxin, the IMCR director Prof Balram Bhargava said Covaxin also worked well against all variant strains of SARS-CoV-2 including the Delta variant.from Industry-Economic Times
Read The Rest:economictimes...
